MedTrace Logo

Induction Chemotherapy for Locally Advanced Esophageal Cancer

NCT03110926 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-12

No results posted yet for this study

Summary

Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced esophageal cancer.

Conditions

  • Esophageal Carcinoma

Interventions

DRUG

mFOLFOX6

Induction Chemotherapy

COMBINATION_PRODUCT

Chemoradiation

Chemoradiation

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Richard Dunne, MD · University of Rochester Wilmot Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-19
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03110926 on ClinicalTrials.gov